Albireo Pharma (NASDAQ: ALBO) recently received a number of ratings updates from brokerages and research firms:

  • 8/14/2019 – Albireo Pharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “
  • 8/13/2019 – Albireo Pharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $25.00 price target on the stock. According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “
  • 8/11/2019 – Albireo Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $62.00 price target on the stock.
  • 8/10/2019 – Albireo Pharma was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/9/2019 – Albireo Pharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $69.00 price target on the stock.
  • 7/24/2019 – Albireo Pharma was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2019 – Albireo Pharma was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/15/2019 – Albireo Pharma had its “buy” rating reaffirmed by analysts at William Blair.
  • 7/11/2019 – Albireo Pharma was given a new $69.00 price target on by analysts at Wedbush. They now have a “buy” rating on the stock.
  • 7/10/2019 – Albireo Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $62.00 price target on the stock.
  • 7/5/2019 – Albireo Pharma was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/2/2019 – Albireo Pharma was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 6/29/2019 – Albireo Pharma was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/23/2019 – Albireo Pharma was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/22/2019 – Albireo Pharma was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 6/17/2019 – Albireo Pharma was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

ALBO traded down $1.31 during trading on Thursday, reaching $22.22. 83,504 shares of the company’s stock were exchanged, compared to its average volume of 50,648. Albireo Pharma Inc has a one year low of $19.10 and a one year high of $38.69. The stock has a market capitalization of $283.77 million, a PE ratio of -5.64 and a beta of 1.52. The stock has a fifty day moving average price of $28.12.

Albireo Pharma (NASDAQ:ALBO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.44) by $0.09. Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.13%. The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.11 million. On average, sell-side analysts expect that Albireo Pharma Inc will post -5.87 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Aperio Group LLC bought a new stake in Albireo Pharma during the 2nd quarter worth approximately $42,000. Meeder Asset Management Inc. boosted its stake in shares of Albireo Pharma by 796.5% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,026 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 1,800 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Albireo Pharma by 356.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 3,328 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,599 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Albireo Pharma by 27.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,836 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 614 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Albireo Pharma by 87.6% in the 4th quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 3,020 shares during the last quarter. 70.59% of the stock is currently owned by hedge funds and other institutional investors.

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Article: Trading Ex-Dividend Strategy

Receive News & Ratings for Albireo Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.